ScoreWhy is Ajanta Pharma Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 12.85% and Operating profit at 9.31% over the last 5 years
2
Flat results in Sep 25
- DEBTORS TURNOVER RATIO(HY) Lowest at 0.34 times
3
With ROE of 22.6, it has a Expensive valuation with a 7.6 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -10.37%, its profits have risen by 11.3% ; the PEG ratio of the company is 3
4
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 1.64% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -10.37% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ajanta Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ajanta Pharma
-10.0%
-0.32
32.82%
Sensex
4.32%
0.36
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.85%
EBIT Growth (5y)
9.31%
EBIT to Interest (avg)
90.37
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
1.08
Tax Ratio
22.03%
Dividend Payout Ratio
78.95%
Pledged Shares
15.28%
Institutional Holding
26.44%
ROCE (avg)
30.01%
ROE (avg)
21.01%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
34
Price to Book Value
7.59
EV to EBIT
28.17
EV to EBITDA
24.70
EV to Capital Employed
8.85
EV to Sales
6.44
PEG Ratio
2.99
Dividend Yield
1.07%
ROCE (Latest)
31.41%
ROE (Latest)
22.56%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET SALES(Q)
Highest at Rs 1,353.73 cr
PAT(Q)
At Rs 260.19 cr has Grown at 20.2%
EPS(Q)
Highest at Rs 20.76
-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.34 times
Loading Valuation Snapshot...
Here's what is working for Ajanta Pharma
Net Sales - Quarterly
Highest at Rs 1,353.73 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 260.19 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 260.19 cr has Grown at 20.2%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 20.76
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Ajanta Pharma
Debtors Turnover Ratio- Half Yearly
Lowest at 0.34 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
Non Operating Income - Quarterly
Highest at Rs 59.34 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
